Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: Biology or Technique? Results from the SEARCH database

European Urology

Volumn 62, Issue 5, 2012, Pages 910-916

  Ho, Tammy ^a,b   Gerber, Leah ^a,b   Aronson, William J ^c,d   Terris, Martha K ^e,f   Presti, Joseph C ^g,h   Kane, Christopher J ⁱ   Amling, Christopher L ^j   Freedland, Stephen J ^a,b,k  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f MEDICAL COLLEGE OF GEORGIA   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h VA PALO ALTO HEALTH CARE SYSTEM   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^k DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Biochemical recurrence; Obesity; Prostate cancer; PSA nadir; Radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; BODY MASS; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY;

AGED; BODY MASS INDEX; HUMANS; KALLIKREINS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 84867069646     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.08.015     Document Type: Article

References (30)

1. K.M. Flegal, M.D. Carroll, C.L. Ogden, and L.R. Curtin Prevalence and trends in obesity among US adults, 1999-2008 JAMA 303 2010 235 241
2. Global database on body mass index. World Health Organization Web site. http://apps.who.int/bmi/index.jsp. Accessed January 25, 2011.
3. M.P. Cleary, and M.E. Grossmann Minireview: obesity and breast cancer: the estrogen connection Endocrinology 150 2009 2537 2542
4. I. Laake, I. Thune, R. Selmer, S. Tretli, M.L. Slattery, and M.B. Veierod A prospective study of body mass index, weight change, and risk of cancer in the proximal and distal colon Cancer Epidemiol Biomarkers Prev 19 2010 1511 1522
5. A.M. Nomura Body size and prostate cancer Epidemiol Rev 23 2001 126 131
6. S.O. Andersson, A. Wolk, and R. Bergstrom Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers J Natl Cancer Inst 89 1997 385 389
7. S.J. Freedland, L.L. Banez, L.L. Sun, N.J. Fitzsimons, and J.W. Moul Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database Prostate Cancer Prostatic Dis 12 2009 259 263
8. E. Giovannucci, E.B. Rimm, and Y. Liu Body mass index and risk of prostate cancer in U.S. health professionals J Natl Cancer Inst 95 2003 1240 1244
9. C. Rodriguez, A.V. Patel, E.E. Calle, E.J. Jacobs, A. Chao, and M.J. Thun Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States Cancer Epidemiol Biomarkers Prev 10 2001 345 353
10. S.J. Freedland, W.J. Aronson, and C.J. Kane Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group J Clin Oncol 22 2004 446 453
11. S.J. Freedland, K.A. Grubb, and S.K. Yiu Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center J Urol 174 2005 919 922
12. S.J. Freedland, K.A. Grubb, and S.K. Yiu Obesity and capsular incision at the time of open retropubic radical prostatectomy J Urol 174 2005 1798 1801
13. S.J. Freedland, M.K. Terris, and J.C. Presti Jr. Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins J Urol 172 2004 520 524
14. D.M. Moreira, J.C. Presti Jr., and W.J. Aronson Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database J Urol 182 2009 2250 2255
15. D.M. Moreira, J.C. Presti Jr., and W.J. Aronson Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database BJU Int 105 2010 1541 1547
16. C.G. Rogers, M.A. Khan, M. Craig Miller, R.W. Veltri, and A.W. Partin Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy Cancer 101 2004 2549 2556
17. S. Shen, H. Lepor, R. Yaffee, and S.S. Taneja Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy J Urol 173 2005 777 780
18. D.M. Moreira, J.C. Presti Jr., and W.J. Aronson The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases Prostate Cancer Prostatic Dis 13 2010 87 93
19. C.L. Amling, R.H. Riffenburgh, and L. Sun Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy J Clin Oncol 22 2004 439 445
20. S.J. Freedland, L. Sun, and C.J. Kane Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases BJU Int 102 2008 969 974
21. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
22. J. Ferlay, D.M. Parkin, and E. Steliarova-Foucher Estimates of cancer incidence and mortality in Europe in 2008 Eur J Cancer 46 2010 765 781
23. C.B. Begg, E.R. Riedel, and P.B. Bach Variations in morbidity after radical prostatectomy N Engl J Med 346 2002 1138 1144
24. A. Naselli, C. Introini, R. Andreatta, B. Spina, M. Truini, and P. Puppo Prognostic factors of persistently detectable PSA after radical prostatectomy Int J Urol 16 2009 82 86
25. M.L. Eisenberg, B.J. Davies, M.R. Cooperberg, J.E. Cowan, and P.R. Carroll Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy Eur Urol 57 2010 622 630
26. S. Sengupta, C.M. Christensen, and H. Zincke Detectable PSA between 60 and 120 days following RP for prostate cancer: natural history and prognostic significance J Urol 176 2006 559 563
27. M.A. Hoffman, W.C. DeWolf, and A. Morgentaler Is low serum free testosterone a marker for high grade prostate cancer? J Urol 163 2000 824 827
28. R. Pasquali, F. Casimirri, and S. Cantobelli Effect of obesity and body fat distribution on sex hormones and insulin in men Metabolism 40 1991 101 104
29. A. Wolk, C.S. Mantzoros, and S.O. Andersson Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study J Natl Cancer Inst 90 1998 911 915
30. L.L. Banez, R.J. Hamilton, and A.W. Partin Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer JAMA 298 2007 2275 2280